Posted On: 04/04/2016 9:37:03 AM
Post# of 23100
$ZFGN Biotech Firm Receives Key Patent Notice
Zafgen, Inc. (ZFGN), a biopharmaceutical company creating treatments for patients affected by obesity and complex metabolic disorders, announced that new scientific data from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Willi syndrome (PWS) during a six-month randomized treatment period, they will be presenting at ENDO 2016 beginning Friday, the Endocrine Society's 98th Annual Meeting & Expo taking place in Boston from April 1-4.
Zafgen, Inc. (ZFGN), a biopharmaceutical company creating treatments for patients affected by obesity and complex metabolic disorders, announced that new scientific data from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Willi syndrome (PWS) during a six-month randomized treatment period, they will be presenting at ENDO 2016 beginning Friday, the Endocrine Society's 98th Annual Meeting & Expo taking place in Boston from April 1-4.
(0)
(0)
IMHO
Always, always do you own DD. Only invest funds you can afford to lose and trust nobody but yourself.
Always, always do you own DD. Only invest funds you can afford to lose and trust nobody but yourself.
